Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ — – RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; – Objective Response and Disease Control Comparable to or better than most…